Literature DB >> 9184771

Cancer and infection: estimates of the attributable fraction in 1990.

P Pisani1, D M Parkin, N Muñoz, J Ferlay.   

Abstract

Various estimates of the proportion of all cancers attributable to infections have been proposed but none have been numerically justified. We have reviewed the evidence for "causality" with respect to infectious agents linked with cancer and estimated the fraction of all cancer cases concerned that are attributable to it. The etiological fraction was applied to the estimated annual incidence of cancer at each specific site in 1990, and the number of attributable cases was obtained. We estimate that 15.6% (1,450,000 cases) of the worldwide incidence of cancer in 1990 can be attributed to infection with either the hepatitis B and C viruses, the human papillomaviruses, EBV, human T-cell lymphotrophic virus I, HIV, the bacterium Helicobacter pylori, schistosomes, or liver flukes. There would be 21% fewer cases of cancer in developing countries (1,000,000 fewer cases per year) and 9% fewer cases in developed countries (375,000 fewer cases per year) if these infectious diseases were prevented. The attributable fraction at the specific sites varies from 89% of cervix cancers attributable to the papillomaviruses to 1% of all leukemias attributable to human T-cell lymphotrophic virus I.

Entities:  

Mesh:

Year:  1997        PMID: 9184771

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  69 in total

Review 1.  Cancer in the developing world: a call to action.

Authors:  S B Jones
Journal:  BMJ       Date:  1999-08-21

2.  Age-incidence relationships and time trends in cervical cancer in Sweden.

Authors:  K Hemminki; X Li; P Mutanen
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

3.  Liver cancer in low and middle income countries.

Authors:  Andrew J Hall; Christopher P Wild
Journal:  BMJ       Date:  2003-05-10

4.  XRCC1 and base excision repair balance in response to nitric oxide.

Authors:  James T Mutamba; David Svilar; Somsak Prasongtanakij; Xiao-Hong Wang; Ying-Chih Lin; Peter C Dedon; Robert W Sobol; Bevin P Engelward
Journal:  DNA Repair (Amst)       Date:  2011-10-29

Review 5.  Helicobacter pylori: the size of the problem.

Authors:  J Parsonnet
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

6.  C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Authors:  Renee C Prins; Brooks L Rademacher; Solange Mongoue-Tchokote; Joshi J Alumkal; Julie N Graff; Kristine M Eilers; Tomasz M Beer
Journal:  Urol Oncol       Date:  2010-03-06       Impact factor: 3.498

7.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

8.  Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18.

Authors:  Valerie Laniosz; Kha C Nguyen; Patricio I Meneses
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar.

Authors:  Ulziibat Shirendeb; Yoshitaka Hishikawa; Shingo Moriyama; Ne Win; Minn Minn Myint Thu; Khin Swe Mar; Gerlee Khatanbaatar; Hideaki Masuzaki; Takehiko Koji
Journal:  Acta Histochem Cytochem       Date:  2009-12-22       Impact factor: 1.938

10.  Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy.

Authors:  Martin Luther Koanga Mogtomo; Louise Carole Gouabe Malieugoue; Carolle Djiepgang; Michel Wankam; Andre Moune; Annie Ngono Ngane
Journal:  Infect Agent Cancer       Date:  2009-06-03       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.